替吉奥联合铂类治疗晚期非小细胞肺癌疗效观察  

Observation of curative effect of S-1 plus cisplatin/carboplatin as second-line chemotherapy in the treatment of patients with advanced non-small-cell lung cancer

作　　者：龙翔宇[1] 戴路明[2] 王新远[1] 周伟[1] 龙建林[1] 王颖[1] 

机构地区：[1]广安市人民医院肿瘤科,四川广安638001 [2]昆明医科大学第一附属医院呼吸二科,云南昆明650000

出　　处：《临床肺科杂志》2014年第6期1083-1085,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察和评价替吉奥联合铂类二线治疗晚期非小细胞肺癌疗效、毒副反应。方法 37例经过三代含铂治疗失败的晚期非小细胞肺癌患者,使用替吉奥胶囊,并加用顺铂或卡铂的二线治疗,观察RR、中位PFS及安全性。结果其中36例患者可评价,获得PR 5例(13.9%),稳定(SD)11例(30.6%),进展(PD)20例(55.5%),无CR者。DCR为44.5%,其中位PFS为4.2月,主要毒副作用均可以耐受。结论替吉奥加顺铂/卡铂为用于二线治疗晚期非小细胞肺癌疗效较好,但需较大样本证实。Objective To evaluate the curative effect, median progression-free survival and adverse reaction of S-1 plus cisplatin/carboplatin as second-line therapy for patients with advanced non-small-cell lung cancer. Meth-ods 37 advanced NLCSC patients failed in third generation platin-based doublet regimens received S-1 plus cispla-tin/carboplatin treatment. RR/DCR, median PFS and safety were observed. Results 36 patients could be evalua-ted. There were 5 patients with PR, 11 with SD and 20 with PD and none of CR. The objective response rates and disease control rates were 13. 9% and 44. 5% respectively. PFS was 4. 2 months. The main toxicities were tolerable. Conclusion The combination of S1 and cisplatin/carboplatin is effective in disease control and well tolerated as sec-ond-line regimen in the treatment of advanced NSCLC.

关 键 词：非小细胞肺癌 替吉奥 化疗 

分 类 号：R734.2[医药卫生—肿瘤]